Circulating cell death products predict clinical outcome of colorectal cancer patients
暂无分享,去创建一个
[1] Alexei Degterev,et al. Expansion and evolution of cell death programmes , 2008, Nature Reviews Molecular Cell Biology.
[2] R. Johnson,et al. Hypoxia: A key regulator of angiogenesis in cancer , 2007, Cancer and Metastasis Reviews.
[3] S. Linder,et al. Cytokeratin-18 Is a Useful Serum Biomarker for Early Determination of Response of Breast Carcinomas to Chemotherapy , 2007, Clinical Cancer Research.
[4] S. Linder,et al. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. , 2007, Lung cancer.
[5] Brian Keith,et al. Hypoxia-Inducible Factors, Stem Cells, and Cancer , 2007, Cell.
[6] M. Ranson,et al. Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma , 2007, Cancer Chemotherapy and Pharmacology.
[7] G. Kramer,et al. Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles , 2006, British Journal of Cancer.
[8] P. Stieber,et al. Apoptotic markers in cancer. , 2004, Clinical biochemistry.
[9] Moonil Kim,et al. Hypoxia Inhibits Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Blocking Bax Translocation , 2004, Cancer Research.
[10] Crispin J. Miller,et al. Hypoxia-Mediated Down-Regulation of Bid and Bax in Tumors Occurs via Hypoxia-Inducible Factor 1-Dependent and -Independent Mechanisms and Contributes to Drug Resistance , 2004, Molecular and Cellular Biology.
[11] G. Kramer,et al. Differentiation between Cell Death Modes Using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18 , 2004, Cancer Research.
[12] H. Hollema,et al. Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas , 2004, Histopathology.
[13] J. Wood,et al. A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera , 2003, Apoptosis.
[14] S. Linder,et al. Measurement of an apoptotic product in the sera of breast cancer patients. , 2003, European journal of cancer.
[15] K. Wiman,et al. A Novel High-Through-Put Assay for Screening of Pro-Apoptotic Drugs , 2002, Investigational New Drugs.
[16] A. Cheung,et al. Apoptotic activity in gestational trophoblastic disease correlates with clinical outcome: assessment by the caspase‐related M30 CytoDeath antibody , 2001, Histopathology.
[17] B. Persson,et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo‐epitope exposed during early apoptosis , 1999, The Journal of pathology.
[18] C. Hauser,et al. Oncogene activation of human keratin 18 transcription via the Ras signal transduction pathway. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[19] Oliver H. Lowry,et al. Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.
[20] H. Hollema,et al. Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. , 2003, Critical reviews in oncology/hematology.